Minimal Disease Activity News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesMoonlake immunotherapeuticsHidradenitis suppurativaKristian reichHadar lev tovMatthias bodenstedtMary jane elliottNamrata taakPatricia sousaAshley tappSethb formanMoonlake nanobodyExchange commissionEuropean medicines agencyMiller school of medicineAmerican college of rheumatology

MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesMoonlake immunotherapeuticsHidradenitis suppurativaKristian reichMoonlake nanobodyMatthias bodenstedtPatricia sousaHadar lev tovAshley tappMary jane elliottSethb formanNamrata taakDrug administrationUniversity of miamiExchange commissionEuropean medicines agency

Methotrexate Exposure May be Linked to Decreased Sexual Function in Men

Researchers investigated the impact of methotrexate exposure on sexual dysfunction among men with inflammatory arthritis. A potential association was found between MTX exposure and decreased sexual function among men with inflammatory arthritis.

International index of erectile functionJoint boneClinical disease activity indexMinimal disease activityInternational indexErectile function

Risankizumab Shows Efficacy in Patients With Active Psoriatic Arthritis Through 52 Weeks

Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.

American college of rheumatologyAmerican collegePsoriasis area severity indexMinimal disease activityLow disease activityRisankizumab efficacyActive psoriatic arthritis

Psoriatic Arthritis Window of Opportunity Within 1 Year of Symptom Onset

Researchers compared lengths of diagnostic delays among patients with psoriatic arthritis to determine whether a window of opportunity exists for improving outcomes. A window of opportunity for better clinical outcomes may exist during the first year after symptom onset in patients with PsA.

Musculoskeletal diseasesEarly psoriatic arthritisMinimal disease activity